| Jeffrey W Coleman, CRNA | |
|
1101 W Liberty St, Farmington, MO 63640-1921 | |
| (573) 756-6451 | |
| Not Available |
| Full Name | Jeffrey W Coleman |
|---|---|
| Gender | Male |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 29 Years |
| Location | 1101 W Liberty St, Farmington, Missouri |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396857405 | NPI | - | NPPES |
| P00267533 | Other | RAIL ROAD |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 107583 (Missouri) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Missouri Baptist Medical Center | Town and country, MO | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Missouri Baptist Medical Center | 3476461955 | 59 |
| Ballas Anesthesia Inc | 5092615310 | 51 |
News Archive
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.
The relatively slow pace of neonatal and under-5 mortality reduction could prevent most countries in sub-Saharan Africa from achieving targets set in Sustainable Development Goal 3 by 2030, according to a study published March 12 in the open-access journal PLOS Medicine by Iván Mejía-Guevara of Stanford University, USA and colleagues.
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 9 days ago
| Entity Name | Washington University |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528005642 PECOS PAC ID: 9830008770 Enrollment ID: O20031118001093 |
News Archive
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.
The relatively slow pace of neonatal and under-5 mortality reduction could prevent most countries in sub-Saharan Africa from achieving targets set in Sustainable Development Goal 3 by 2030, according to a study published March 12 in the open-access journal PLOS Medicine by Iván Mejía-Guevara of Stanford University, USA and colleagues.
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 9 days ago
| Entity Name | Ballas Anesthesia Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1306894241 PECOS PAC ID: 5092615310 Enrollment ID: O20040112000519 |
News Archive
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.
The relatively slow pace of neonatal and under-5 mortality reduction could prevent most countries in sub-Saharan Africa from achieving targets set in Sustainable Development Goal 3 by 2030, according to a study published March 12 in the open-access journal PLOS Medicine by Iván Mejía-Guevara of Stanford University, USA and colleagues.
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 9 days ago
| Entity Name | Missouri Baptist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467461434 PECOS PAC ID: 3476461955 Enrollment ID: O20041013000043 |
News Archive
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.
The relatively slow pace of neonatal and under-5 mortality reduction could prevent most countries in sub-Saharan Africa from achieving targets set in Sustainable Development Goal 3 by 2030, according to a study published March 12 in the open-access journal PLOS Medicine by Iván Mejía-Guevara of Stanford University, USA and colleagues.
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 9 days ago
| Entity Name | Anesthesia Partners Ltd |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043270465 PECOS PAC ID: 3870557986 Enrollment ID: O20041118000270 |
News Archive
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.
The relatively slow pace of neonatal and under-5 mortality reduction could prevent most countries in sub-Saharan Africa from achieving targets set in Sustainable Development Goal 3 by 2030, according to a study published March 12 in the open-access journal PLOS Medicine by Iván Mejía-Guevara of Stanford University, USA and colleagues.
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 9 days ago
| Entity Name | Missouri Baptist Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609658905 PECOS PAC ID: 3476461955 Enrollment ID: O20240111001744 |
News Archive
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.
The relatively slow pace of neonatal and under-5 mortality reduction could prevent most countries in sub-Saharan Africa from achieving targets set in Sustainable Development Goal 3 by 2030, according to a study published March 12 in the open-access journal PLOS Medicine by Iván Mejía-Guevara of Stanford University, USA and colleagues.
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeffrey W Coleman, CRNA 1101 W Liberty St, Farmington, MO 63640-1921 Ph: (573) 756-6451 | Jeffrey W Coleman, CRNA 1101 W Liberty St, Farmington, MO 63640-1921 Ph: (573) 756-6451 |
News Archive
Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension
Waters Corporation has posted a new version of its online video showcase featuring compelling interviews with more than 50 scientists, development partners, and product experts in the fields of pharmaceutical discovery and development, food safety, environmental analysis, sports medicine, disease research and clinical toxicology and clinical research.
The relatively slow pace of neonatal and under-5 mortality reduction could prevent most countries in sub-Saharan Africa from achieving targets set in Sustainable Development Goal 3 by 2030, according to a study published March 12 in the open-access journal PLOS Medicine by Iván Mejía-Guevara of Stanford University, USA and colleagues.
Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.
Risk of congestive heart failure in women treated with trastuzumab (Herceptin) and combination chemotherapy for early-stage breast cancer did not increase over time according to a five-year follow-up of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-31, presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago.
› Verified 9 days ago
Richard C Dore', RN, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1212 Weber Rd, Farmington, MO 63640 Phone: 573-756-4581 | |
Barbara J Anderson, RN, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1212 Weber Rd, Farmington, MO 63640 Phone: 573-756-4581 | |
Mr. Gregory Brent Reed, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1101 W Liberty St, Farmington, MO 63640 Phone: 573-760-8025 Fax: 573-760-8006 | |
James A Smith, RN, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 400 Parkland Dr, Farmington, MO 63640 Phone: 573-756-8000 Fax: 573-756-8288 | |
Mr. Charles Goshen, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1101 W Liberty St, Farmington, MO 63640 Phone: 573-756-6751 | |
Thomas D Wills Iii, C.R.N.A Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 1101 W Liberty St, Farmington, MO 63640 Phone: 573-756-6451 |